Literature DB >> 12359513

Speed congenics: applications for transgenic and knock-out mouse strains.

G T Wong1.   

Abstract

Genetically modified mice are mainstream tools for medical research. The background strains used to generate transgenic and knockout mice have been studied extensively. In many instances, the background strain used to create the genetic modification is inappropriate for phenotypic analysis of the mutation. In such cases it is useful to develop a congenic strain of the transgenic mouse line in which the mutation is introduced into a more suitable genetic background. In this review, the approaches to generate congenic strains of transgenic and knockout mice will be discussed. In particular, marker-assisted selection protocols (MASP) will be discussed in detail to generate congenic strains in an accelerated fashion ("speed congenics").

Entities:  

Mesh:

Year:  2002        PMID: 12359513     DOI: 10.1054/npep.2002.0905

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  21 in total

1.  Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice.

Authors:  Patricia K A Mongini; Jill M Kramer; Tomo-O Ishikawa; Harvey Herschman; Donna Esposito
Journal:  Clin Immunol       Date:  2014-03-29       Impact factor: 3.969

2.  A comprehensive SNP-based genetic analysis of inbred mouse strains.

Authors:  Shirley Tsang; Zhonghe Sun; Brian Luke; Claudia Stewart; Nicole Lum; Melissa Gregory; Xiaolin Wu; Marianne Subleski; Nancy A Jenkins; Neal G Copeland; David J Munroe
Journal:  Mamm Genome       Date:  2005-07       Impact factor: 2.957

3.  Assessment of feeding behavior in laboratory mice.

Authors:  Kate L J Ellacott; Gregory J Morton; Stephen C Woods; Patrick Tso; Michael W Schwartz
Journal:  Cell Metab       Date:  2010-07-07       Impact factor: 27.287

4.  Ablation of the cardiac ryanodine receptor phospho-site Ser2808 does not alter the adrenergic response or the progression to heart failure in mice. Elimination of the genetic background as critical variable.

Authors:  Francisco J Alvarado; Xi Chen; Héctor H Valdivia
Journal:  J Mol Cell Cardiol       Date:  2017-01-06       Impact factor: 5.000

Review 5.  Genetically manipulated mouse models of lung disease: potential and pitfalls.

Authors:  Rebecca M Baron; Alexander J S Choi; Caroline A Owen; Augustine M K Choi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-23       Impact factor: 5.464

6.  Generation of gene knockout mice by ES cell microinjection.

Authors:  Glenn Longenecker; Ashok B Kulkarni
Journal:  Curr Protoc Cell Biol       Date:  2009-09

7.  Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domains.

Authors:  Maho Morishima-Kawashima; Xianlin Han; Yu Tanimura; Hiroki Hamanaka; Mariko Kobayashi; Takashi Sakurai; Minesuke Yokoyama; Koji Wada; Nobuyuki Nukina; Shinobu C Fujita; Yasuo Ihara
Journal:  J Neurochem       Date:  2007-05       Impact factor: 5.372

8.  Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.

Authors:  V Labrie; W Wang; S W Barger; G B Baker; J C Roder
Journal:  Genes Brain Behav       Date:  2009-08-05       Impact factor: 3.449

9.  Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).

Authors:  Paola Rojas; Fernando Benavides; Jorge Blando; Carlos Perez; Kim Cardenas; Ellen Richie; Erik S Knudsen; David G Johnson; Adrian M Senderowicz; Marcelo L Rodriguez-Puebla; Claudio J Conti
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

10.  Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice.

Authors:  A Gomori; A Ishihara; M Ito; H Matsushita; M Ito; S Mashiko; H Iwaasa; M Matsuda; M A Bednarek; S Qian; D J Macneil; A Kanatani
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.